Literature DB >> 7852280

Purification and characterization of galactocerebrosidase from human lymphocytes.

N Sakai1, K Inui, M Midorikawa, Y Okuno, S Ueda, A Iwamatsu, S Okada.   

Abstract

Galactocerebrosidase was purified about 22,600-fold using several hydrophobic column and gel filtration steps with a 4.8% recovery, from human lymphocytes. Its specific activity was 1.54 x 10(5) nmol/h/mg with tritium-labeled galactocerebroside as the substrate in the taurocholate system. The optimal pH for galactocerebroside was 4.2 in the taurocholate system and 4.6 in the cholate system. The Km values for galactocerebroside were 5 microM in the taurocholate system and 25 microM in the cholate system. The molecular weight of the purified enzyme was estimated to be 90 kDa by sodium dodecylsulfate polyacrylamide gel electrophoresis and gel filtration. However, 70, 50, 40, and 30 kDa bands were also recognized on SDS-PAGE. The N-terminal amino acid sequences of the 70 kDa molecule and the three 50 kDa molecules were the same as that of the 90 kDa molecule. The N-terminal amino acid sequences of the 40 and 30 kDa molecules were unique. A monoclonal antibody raised against the purified enzyme effectively immunoprecipitated galactocerebrosidase activity, and an affinity column prepared with this monoclonal antibody bound the 90 and 50 kDa proteins. These results suggest that this enzyme is probably processed from the 90 kDa protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7852280     DOI: 10.1093/oxfordjournals.jbchem.a124569

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  6 in total

1.  Molecular heterogeneity of Krabbe disease.

Authors:  L Fu; K Inui; T Nishigaki; N Tatsumi; H Tsukamoto; C Kokubu; T Muramatsu; S Okada
Journal:  J Inherit Metab Dis       Date:  1999-04       Impact factor: 4.982

2.  Insights into Krabbe disease from structures of galactocerebrosidase.

Authors:  Janet E Deane; Stephen C Graham; Nee Na Kim; Penelope E Stein; Rosamund McNair; M Begoña Cachón-González; Timothy M Cox; Randy J Read
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

3.  Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.

Authors:  Fredj Ben Bdira; Marta Artola; Herman S Overkleeft; Marcellus Ubbink; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2018-10-02       Impact factor: 5.922

4.  Structural snapshots illustrate the catalytic cycle of β-galactocerebrosidase, the defective enzyme in Krabbe disease.

Authors:  Chris H Hill; Stephen C Graham; Randy J Read; Janet E Deane
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

5.  Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants.

Authors:  Samantha J Spratley; Chris H Hill; Agnete H Viuff; James R Edgar; Karsten Skjødt; Janet E Deane
Journal:  Traffic       Date:  2016-05-30       Impact factor: 6.215

6.  Transduction of cultured oligodendrocytes from normal and twitcher mice by a retroviral vector containing human galactocerebrosidase (GALC) cDNA.

Authors:  E Costantino-Ceccarini; A Luddi; M Volterrani; M Strazza; M A Rafi; D A Wenger
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.